Overcoming imatinib resistance in chronic myelogenous leukemia cells using non-cytotoxic cell death modulators.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2019.111748
Abstract: Recent studies examined the possibility to overcome imatinib resistance in chronic myeloid leukemia (CML) patients by combination therapy with peroxisome proliferator-activated receptor gamma (PPARγ) ligands. Pioglitazone, a full PPARγ agonist, improved the survival of patients… read more here.
Keywords: ppar; resistance chronic; imatinib resistance; resistance ... See more keywords
Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies
Sign Up to like & getrecommendations! Published in 2020 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2020.1797482
Abstract: ABSTRACT Introduction Development of the BTK inhibitor ibrutinib has changed the landscape of CLL treatment producing durable responses with minimal to no myelosuppression. Although remissions are durable, relapses remain a challenge. Areas covered Data from… read more here.
Keywords: resistance chronic; treatment; mechanisms ibrutinib; resistance ... See more keywords
miR-9 regulates the multidrug resistance of chronic myelogenous leukemia by targeting ABCB1
Sign Up to like & getrecommendations! Published in 2019 at "Oncology Reports"
DOI: 10.3892/or.2019.7057
Abstract: Following the publication of this article, the authors have subsequently realized that Fig. 2D (lower middle panel, K562‑control group treated with paclitaxel) contained the same data as the left lower panel (K562 group). The authors have… read more here.
Keywords: regulates multidrug; resistance chronic; panel k562; mir regulates ... See more keywords